WO2003008635A8 - η-SECRETASE IN VITRO SCREENING ASSAY - Google Patents

η-SECRETASE IN VITRO SCREENING ASSAY

Info

Publication number
WO2003008635A8
WO2003008635A8 PCT/EP2002/007095 EP0207095W WO03008635A8 WO 2003008635 A8 WO2003008635 A8 WO 2003008635A8 EP 0207095 W EP0207095 W EP 0207095W WO 03008635 A8 WO03008635 A8 WO 03008635A8
Authority
WO
WIPO (PCT)
Prior art keywords
secretase
screening assay
vitro screening
substrate
secretase activity
Prior art date
Application number
PCT/EP2002/007095
Other languages
French (fr)
Other versions
WO2003008635A3 (en
WO2003008635A2 (en
Inventor
Cornelia Dorner-Ciossek
Klaus Fuchs
Christian Haass
Markus Kostka
Harald Steiner
Original Assignee
Boehringer Ingelheim Pharma
Cornelia Dorner-Ciossek
Klaus Fuchs
Christian Haass
Markus Kostka
Harald Steiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Cornelia Dorner-Ciossek, Klaus Fuchs, Christian Haass, Markus Kostka, Harald Steiner filed Critical Boehringer Ingelheim Pharma
Priority to JP2003514950A priority Critical patent/JP2004535206A/en
Priority to MXPA03011898A priority patent/MXPA03011898A/en
Priority to CA002452832A priority patent/CA2452832A1/en
Priority to EP02745414A priority patent/EP1407043A2/en
Publication of WO2003008635A2 publication Critical patent/WO2003008635A2/en
Publication of WO2003008635A8 publication Critical patent/WO2003008635A8/en
Publication of WO2003008635A3 publication Critical patent/WO2003008635A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

According to the screening method of the invention substances capable of modulating η-secretase activity are identified by incubating a source and a substrate of η-secretase activity with a test substance and detecting a C-terminal fragment released from said substrate.
PCT/EP2002/007095 2001-07-04 2002-06-27 η-SECRETASE IN VITRO SCREENING ASSAY WO2003008635A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003514950A JP2004535206A (en) 2001-07-04 2002-06-27 In vitro screening assay for γ-secretase
MXPA03011898A MXPA03011898A (en) 2001-07-04 2002-06-27 gamma-SECRETASE IN VITRO.
CA002452832A CA2452832A1 (en) 2001-07-04 2002-06-27 .gamma.-secretase in vitro screening assay
EP02745414A EP1407043A2 (en) 2001-07-04 2002-06-27 Gamma-secretase in vitro screening assay

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10131899.5 2001-07-04
DE10131899A DE10131899A1 (en) 2001-07-04 2001-07-04 In Vitro Screening Assay for Gamma Secretase

Publications (3)

Publication Number Publication Date
WO2003008635A2 WO2003008635A2 (en) 2003-01-30
WO2003008635A8 true WO2003008635A8 (en) 2003-10-30
WO2003008635A3 WO2003008635A3 (en) 2004-01-29

Family

ID=7690254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007095 WO2003008635A2 (en) 2001-07-04 2002-06-27 η-SECRETASE IN VITRO SCREENING ASSAY

Country Status (6)

Country Link
EP (1) EP1407043A2 (en)
JP (1) JP2004535206A (en)
CA (1) CA2452832A1 (en)
DE (1) DE10131899A1 (en)
MX (1) MXPA03011898A (en)
WO (1) WO2003008635A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229582D0 (en) * 2002-12-19 2003-01-22 Merck Sharp & Dohme Novel assay
SI1849762T1 (en) 2006-04-21 2009-12-31 Cellzome Ltd Substituted biphenyl carboxylic acids and derivatives thereof
SI2132188T1 (en) 2007-03-07 2012-04-30 Janssen Pharmaceutica Nv Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators
WO2008109737A1 (en) 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators
JP2010533478A (en) * 2007-07-13 2010-10-28 エラン ファーマシューティカルズ，インコーポレイテッド Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
ES2395083T3 (en) 2007-10-17 2013-02-08 Janssen Pharmaceutica, N.V. Biphenylcarboxylic acids and their derivatives
AU2008312371B2 (en) 2007-10-19 2013-06-20 Janssen Pharmaceutica, N.V. Amine linked modulators of gamma-secretase
JP5439381B2 (en) 2007-10-19 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Piperidinyl and piperazinyl modulators of γ-secretase
AU2008312653B2 (en) 2007-10-19 2013-03-07 Janssen Pharmaceutica, N.V. Amide linked modulators of y-secretase
WO2009052334A1 (en) 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
US7968725B2 (en) 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase
US9023767B2 (en) 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
CN103502466A (en) 2010-09-07 2014-01-08 斯隆－凯特林纪念癌症中心 Methods and compositions for gamma-secretase assay
US10030260B2 (en) 2012-10-16 2018-07-24 The Johns Hopkins University Inducible reconstitution and real-time quantitative kinetic system for the study of intramembrane enzymes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4589297A (en) * 1996-10-07 1998-05-05 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
DE19941039A1 (en) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-secretase in vitro test system

Also Published As

Publication number Publication date
MXPA03011898A (en) 2004-03-26
WO2003008635A3 (en) 2004-01-29
WO2003008635A2 (en) 2003-01-30
DE10131899A1 (en) 2003-02-27
JP2004535206A (en) 2004-11-25
EP1407043A2 (en) 2004-04-14
CA2452832A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2003008635A3 (en) η-SECRETASE IN VITRO SCREENING ASSAY
HUP0200400A2 (en) Protein isolation and analysis
WO2004070351A3 (en) Protein fragment complementation assays for high-throughput and high-content screening
AU2001251291A1 (en) Ubiquitin ligase assay
WO2000004382A8 (en) Arrays of proteins and methods of use thereof
AU5442200A (en) Encoding and decoding of array sensors utilizing nanocrystals
WO2005050224A3 (en) Small molecule and peptide arrays and uses thereof
PT1015608E (en) TEST METHODS OF RECEIVING ACTIVITY AND USEFUL BUILDINGS IN THESE METHODS
NO20044051L (en) Assay for ACTRIIB kinase activity
HK1068154A1 (en) Anaplastic lymphoma kinase assay, reagent and compositions thereof
DE60009575D1 (en) DETECTION OF BACTERIA AND BACTERIOPHAGES WITH IMMOBILIZED ENZYME SUBSTRATES
ATE336721T1 (en) HIGH-THROUGHPUT ASSAY TO MEASURE CELLULAR RESPONSES USING MICROARRAYS
EP2312313A3 (en) Immobilized probes and methods of detecting conformationally altered prion proteins
WO2002047535A3 (en) High throughput assay to detect inhibitors of the map kinase pathway
EP1111385A3 (en) Enzyme-protein complex
AU5143099A (en) Protein fragment complementation assays for the detection of biological or drug interactions
AU2002324902A1 (en) Serine/threonine hydrolase proteins and screening assays
WO2008033992A3 (en) High throughput screening assay for histone modifying enzyme modulators
WO2002000719A3 (en) Human and mouse g-protein couipled receptors
WO2005014616A3 (en) Complexes of gpcr142 and relaxin3 or insl5, and their production and use
AU5971598A (en) Novel antibody, renin-active substance containing the same and prorenin assay reagent using the same
AU2003252383A1 (en) Test piece for protein assay and process for producing the same
WO2000077518A3 (en) Methods and compositions for opsonophagocytic assays
GB0305656D0 (en) Screening assay
AU7825500A (en) Inhibition enzyme linked immunosorbent assay (iELISA) for the detection and quantification of antibodies in biological samples

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 05/2003 DELETE "(72) INVENTOR (FOR US ONLY): HAASS, CHRISTIAN; ICHORING 29 A, 82057ICKING (DE)." AND UNDER (72, 75) ADD "HAASS, CHRISTIAN [DE/DE]; ICHORING 29 A, 82057 ICKING (DE)."

Free format text: IN PCT GAZETTE 05/2003 DELETE "(72) INVENTOR (FOR US ONLY): HAASS, CHRISTIAN; ICHORING 29 A, 82057 ICKING (DE)." AND UNDER (72, 75) ADD "HAASS, CHRISTIAN [DE/DE]; ICHORING 29 A, 82057 ICKING (DE)."

WWE Wipo information: entry into national phase

Ref document number: 2002745414

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011898

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2452832

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003514950

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002745414

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002745414

Country of ref document: EP